Another Setback For Lexicon, But Not In Diabetes
Lexicon Pharmaceuticals continues to see its pipeline winnowed down by clinical trial failures.
's Top #PreMarket Losers
Krispy Kreme Doughnuts dipped 14.05% to $21.10 after the company issued downbeat forecast for fiscal 2015.
Lexicon Pharmaceuticals falls on LX1033 top-line data
Although top-line results from a Phase 2 study of LX1033 in IBS-d showed patients experienced "significant improvements over time," the company says "differences between placebo and LX1033 in stool consistency were not statistically significant."
Lexicon Pharmaceuticals To Host 2013 Research And Development Day
Lexicon Pharmaceuticals, Inc. will hold its R&D Day on Thursday, December 5, 2013 from 9:00 a.m. to 12:00 p.m. Eastern Time at the Yale Club, 50 Vanderbilt Ave., in New York City.
Lexicon To Present At The Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals, Inc. announced today that Lexicon management will present at the Jefferies Global Healthcare Conference on Wednesday, November 20, at 1:40 PM GMT in London.
With 'Progress' Like Lexicon's, Who Needs Failure?
Another quarter is in the books and the biggest question around Lexicon Pharmaceuticals remains unanswered.
Lexicon Pharmaceuticals' CEO Discusses Q3 2013 Results - Earnings Call Transcript
Thank you for holding. Welcome to the Lexicon Pharmaceuticals Third Quarter 2013 Conference Call.
Lexicon to Report Third Quarter Financial Results on November 12, 2013
Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the third quarter at ) or 970-300-1531 .